For international manufacturers
Cytolix is the accountable in-country partner for international manufacturers entering Nepal — from regulatory assessment and registration to controlled import, market development and nationwide distribution.
Why Nepal
Nepal’s domestic industry supplies a substantial share of the national market. Specialised oncology therapies, biologicals, vaccines and complex injectables, however, continue to depend on qualified international manufacturing and responsible in-country representation.
For a manufacturer with the right regulatory credentials, the barrier to entry is administrative rather than competitive.
Published trade data indicates strong growth in pharmaceutical imports. For a qualified manufacturer, the opportunity is not simply shipment volume; it is building a compliant, durable position in therapeutic categories where dependable supply remains important.
Nepal’s drug regulator has issued repeated public notices concerning the availability of cancer medicines, platinum-group chemotherapy agents and immunosuppressants. When a regulator publishes shortage notices, the demand question is already answered.
Nepal records over 20,500 new cancer cases annually, with cancer among the leading causes of death from non-communicable disease. Chronic kidney disease carries a comparably heavy and under-served burden.
Why Cytolix
Most distributors begin with a price list. We begin with a regulatory question: can this product actually be registered in Nepal, and on what evidence? Everything else follows from the answer.
The distinction we apply. A GMP certificate covers a facility. A marketing authorisation covers a product. These are not interchangeable, and treating them as though they were is the most common reason a registration attempt fails. We verify at product level — authorisation number, issuing authority and current status — before committing to a filing.
Authorities we prioritise
Registration pathway
Uncertainty about process and timeline is what stalls most market-entry decisions. This removes it.
Verify the marketing authorisation and confirm a viable Nepal pathway.
Prepare the applicable dossier, certificates and legalised documents.
File with DDA and coordinate queries, samples and testing support.
Obtain applicable recommendations and complete licensed import and customs processes.
Launch only after approval, then pursue eligible formulary, tender and channel opportunities.
Indicative timeline. Typically nine to eighteen months from receipt of a complete dossier to a marketable registration. The single largest variable is documentation completeness, which is why we front-load stage two.
| Stage | What happens | Who is responsible |
|---|---|---|
| 1 Assess | Product selection, verification of marketing authorisation and manufacturing site status, and confirmation that a viable registration route exists. | Cytolix, with information from you |
| 2 Document | Compilation of the registration dossier, certificate of pharmaceutical product, free sale certificate, and legalisation or apostille. | You supply; Cytolix compiles |
| 3 Submit | Filing with the Department of Drug Administration, response to regulatory queries, samples and testing support. | Cytolix |
| 4 Authorise import | Applicable DDA recommendation, licensed import, customs clearance and any required price-related compliance. | Cytolix |
| 5 Market access | Post-approval launch, eligible formulary and tender participation, and compliant scientific communication. | Cytolix |
Division of responsibility
| Cytolix delivers | You provide |
|---|---|
| Regulatory registration and lifecycle maintenance with DDA Nepal | Product dossier, CoPP, free sale certificate and legalised documentation |
| Import licensing, customs clearance, duty and tax handling | Site GMP evidence and marketing authorisation documentation |
| Warehousing, cold-chain storage and nationwide distribution | Commercial terms, minimum order quantities, lead times and shelf life |
| Hospital listing, tender participation and institutional sales | Product training, scientific literature and technical support |
| Scientific communication consistent with approved product information | Approved artwork, packaging specifications, product information and brand guidelines |
| Market intelligence, forecasting and pharmacovigilance reporting | Supply against agreed forecasts |
Partnership structures
The commercial structure can vary, but every route remains subject to current DDA company approval, product registration, import recommendation, licensing and channel requirements.
| Model | How it works | Suits |
|---|---|---|
| Exclusive Nepal representation | The manufacturer authorises Cytolix for agreed products. Following the required DDA approvals, Cytolix manages registration, licensed import, compliant promotion and distribution under an exclusive agreement. | Manufacturers seeking one accountable in-country partner. |
| Product-specific registration and import | The manufacturer appoints Cytolix for selected products. Commercial supply begins only after the applicable company, product and import approvals are in place. | Manufacturers entering Nepal with a focused initial portfolio. |
| Institutional and tender channel | Cytolix participates in eligible hospital or government procurement for registered products, subject to tender conditions and supply through appropriately licensed channels. | Products primarily used by hospitals, treatment centres or public programmes. |
| Staged portfolio entry | Cytolix assesses the portfolio and sequences registration of selected products before later expansion. No unregistered commercial supply is implied; any exceptional import requires specific written DDA permission under the applicable guidance. | Manufacturers that want a measured, evidence-led Nepal launch. |
Regulatory note: These are commercial partnership structures, not exemptions from Nepalese law. Final eligibility depends on the product, manufacturer, current DDA requirements and any product-specific restrictions. A confidentiality agreement can be executed before dossier or commercial information is exchanged.
Supply chain
Operational due diligence usually comes down to one question: can these people physically handle my product without compromising it?
Inspected and reconciled against documentation
Segregated by product class and monitored
8 major centres and 42 sub-distribution channels
Batch records maintained through the controlled route
Storage areas are segregated by product class. Capacity, qualification records and controlled-ambient specifications are shared during technical due diligence.
Cold-chain equipment, validated temperature ranges, monitoring records and documented excursion handling are reviewed against each product’s requirements before appointment.
Submit your portfolio
Share your product list and the regulatory status of each item. We will come back to you within two working days. Nothing you send is shared outside Cytolix.
Submissions are directed to partnerships@cytolix.com.
If you would rather discuss before sending documents, contact our partnerships desk directly.